Kymera Therapeutics, Inc. Common Stock
KYMRStock
$113.99+149.62%52W
Market Cap$9.39B
P/E—
Div yield—
Beta1.94
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)43.90%
Price vs S&P 500 (4W)31.35%
VGM Score48.16
Market Capitalization$9.39B
Earnings Surprise History
Q1 26-0.71est. -0.90
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.31
4.31
4.30
4.28
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KYMRKymera Therapeutics, Inc. Common Stock | F | C | B | $113.99 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule medicines targeting STAT6, TYK2, and IRAK4—proteins with known disease-causing biology that remain undrugged or inadequately treated with existing therapies. The company uses proprietary technologies to overcome limitations that have previously prevented effective drug development against these targets. Its disease-agnostic approach aims to generate a differentiated pipeline addressing multiple therapeutic areas with these validated biological targets.